Dfb Pharmaceuticals, Inc.

Smith + Nephew

Dfb Technology Holdings, LLC

Eric Rolland

Christopher Rinsch

Thomas Hunziker

Beatrice Mis

Beatrice Chevallay

A kit is disclosed that includes a first component comprising alginate, wherein the first component is comprised in a first sterile vile, and a second component comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF&#x3b2;, angiopoietin, EGF, IL-I&#x3b2;, TGF&#x3b1;, and TNF&#x3b1;, wherein the cells are allogeneic and mitotically inactive, a buffered solution, and human serum albumin or a cryoprotectant, wherein the second component is comprised in a second vial.

Methods and compositions for tissue regeneration

A kit is disclosed that includes a first component comprising alginate, wherein the first component is comprised in a first sterile vial, and a second component comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF&#x3b2;, angiopoietin, EGF, IL-I&#x3b2;, IL-6, IL-8, TGF&#x3b1;, and TNF&#x3b1;, wherein the cells are allogeneic and mitotically inactive, a buffered solution, and human serum albumin or a cryoprotectant, wherein the second component is comprised in a second sterile vial.

Disclosed is a method of treating a wound comprising applying a composition to a wound site on a patient in need of wound treatment, wherein the composition comprises mitotically inactive allogeneic cells that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF&#x3b2;, angiopoietin, EGF, IL-I&#x3b2;, IL-6 IL-8, TGF&#x3b1;, and TNF&#x3b1;, and wherein the cells are keratinocytes or fibroblasts, or mixtures thereof.

Disclosed is a kit comprising a first component comprising fibrinogen, aprotinin, and a buffered solution, and a second component comprising, fibroblasts, keratinocytes, thrombin, glycerol, human serum albumin, and a buffered solution, wherein the first and second components are comprised in separate sterile containers.

The present invention provides the use and composition of matter of angiogenic or other growth/cytokine factors expressed by mixtures of allogeneic human cell strains or lines of various types and stages of differentiation. Also provided are unencapsulated preparations (mixed with or applied to extracellular matrix material or synthetic biocompatible substances) for the purpose of temporary application to wounds or defects in the skin or other tissues for the restoration of blood supplying connective tissue to enable organ-specific cells to reestablish organ integrity as well as to inhibit excessive scar formation.

Growing community of inventors

Divonne Les Bains, France

Eric Rolland